Research - Page 7 of 10 - Fideres

Are Options Investors Adequately Compensated in Securities Litigation?

Class definition in securities fraud claims is often restricted to shares, neglecting the holders of options who are also damaged.

February 18, 2019

Pay-to-Delay: Biosimilars And The Cost Of Competition

Biosimilar drugs are non-generic alternatives to traditional biologic medicines, that sell at a fraction of the price. Scrutiny of pay-to-delay

January 29, 2019

Patisserie Valerie’s Bitter Aftertaste: A Forensic Accounting Tale

The holding company of UK café chain Patisserie Valerie is facing financial turmoil after discovering significant and potentially fraudulent accounting

November 28, 2018

The Hidden Cost Of No-Poach Agreements

Fideres’s investigation found preliminary economic evidence to suggest widespread wage suppression in occupations within the healthcare and fast-food sectors between

September 3, 2018

Europe’s Truck Cartel: Collusion on the Road

European Commission decisions of 2016 and 2017 found six European truck manufacturers guilty of price-fixing for a 14-year period. To

September 3, 2018

Dream Sold, Reality Bit: The Mis-Selling of Financial Hedging Products

Fideres shows that commercial borrowers may have significantly overpaid on interest payments as a result of banks selling unsuitable hedging

Municipal Bonds: Low Yields, High Questions

Fideres finds that underwriters systematically misprice US municipal bonds (“Muni Bonds”). We estimate that, between 2006 and 2015, municipal bond

Structured Ratings: Credit Agencies Revisited

It is generally accepted that rating agencies did a poor job rating structured credit products in the years leading up

January 16, 2018

Passing The Buck: When Damages End Up Elsewhere

Fideres explores the available economic methods used to estimate pass-on damages. We present two approaches that avoid common issues in

December 8, 2017